Member Info for sajy

XF-73 is being developed for the following indications

Post surgical infections

Superficial skin infections

Burns and wounds

Diabetic foot ulcer

I am suspecting that the TAM for the above is >$5B

#Dest Mcap £60M.

I have been saying that for months, read my posting history on DEST. Glad to have it confirmed by the experts.

Dr Love - Destiny developing dermal form of XF-73 for Diabetic foot ulcer. My understanding is that the TAM for Diabetic foot ulcer is about $8Billion. Wow

Chris said he joined Destiny because of XF-73, that is music to my ears, as you know what I have been saying about it for a while(Blockbuster).

It is abundantly clear he wants a really big pharma as a partner and as a result expect some very big numbers in the deal.

For those that have been reading my posts will know that I have been saying for a while that XF-73 will be a blockbuster drug and have even gone as far saying that it will be the standard of care for virtually every operation in the future. Todays update is no surprise to me and only reinforces my conviction.

The NIAID update on work done on wounds and burns due this quarter will be just as good and add to the growing body of evidence that XF-73 is a blockbuster in the making.

Surprised2 you have now been filtered as I do not have time for idiots. My post did say it was my gut feeling and that means my thoughts and not what the company have said. So get of your high horse and stop making accusations. It's idiots like you that prevent people posting, from now on I will keep my thoughts to myself.

Rene did attend the conference but decided against presenting the data. What could be the reason for this? Well we know that they have generated good data as stated in the recent Rns, so it's not because the data was not good. We also know that they are in discussions with third parties to sign deals. My gut feeling is that Rene have been asked not to reveal the latest data while discussions are ongoing by the third parties. I believe once a deal or deals have been signed then we will get a more comprehensive update on the data.

To listen to the interview see link below.

https://voxmarkets.co.uk/articles/chris-tovey-ceo-of-destiny-pharma-destiny-is-a-bit-of-a-unicorn-in-the-uk-ca7e04b/

@DestinyPharma

@VOXmarkets

I think this is more for institutions and with Chris track record he is more likely to convince them to come on board. He is not wasting anytime and shows he means business, less than a month in the job.

Watched the IM presentation. As you all know I have said many times that I think XF-73 is going to be a blockbuster drug, well that was more or less confirmed by Chris today. They are talking to multiple global parties and they are not rushing the deal. This shows how important this deal is to the company and how highly they value XF-73. I had heard that both GSK and Pfizer were interested but I think other global pharma are also interested. I am expecting a deal with some pretty large numbers in it.

Also what stood out for me is that Chris said that Destiny Pharma is in a better position than GW pharma was in when I joined it, GW was acquired for $7.2Billion.

My take on the Rns today. Progress with XF-73 has been slow and is likely to be completed in Q1 2024, so delayed by a quarter. The NIAID trial results have also been delayed from Q3 to Q4. Overall a little disappointed but its a long term hold for me so no big deal as I am prepared to wait. Markets do not like delays hence the drop. On the positive side it looks like a lot of big pharma are interested in XF-73 and the company is taking it's time to select the best partner.

Had a chat with IR today. No change to the guidance for SS, still expecting to issue AD by end of September for now. I asked if the company could extend the deadline beyond September if they needed to and was told yes they can and it is not an issue.

Asked why no Rns for the recent court case win against Citibank. Told legally advice is to not Rns news re Chad while ICC case ongoing, also do not want to add fuel to fire. Asked any chance of negotiating a settlement with Chad Gov and told highly unlikely.

Asked why no news or updates last few months, told it's been a quiet period. Company will be issuing interims report before end of September and also got the feeling other news also imminent. Asked if AK could do a presentation for the interims, request will be passed to Ak.

Although we have had no news got the impression things a progressing well behind the scenes and we are likely to get a few updates soon.

I am surprised Dest has not been tipped in any papers, considering how much it has going for it. I think it is very cheap even at this price, hence my large holding. Right here goes, predicting Dest will soon be tipped in one of the papers. GLA

Monkey, the TAM for XF-73 for USA alone for post surgical infections is $2B. The TAM for Superficial skin infections is $3.5B and not sure what the TAM is for wounds. Total likely to be around $7B for all 3 indications and that's just for XF-73 and nothing else. Dest Mcap £52M, go figure.

CT starts tomorrow, so I would say the chances of an Rns next week is high. The CFO and CSO are very busy to talk both this week and next, so something is happening.

Expect this buying to continue as we are entering a news rich period and the possibility of transformational news will result in fomo for many. Those that sold few weeks back will be buying back in.

I think interest in Dest will increase this week and with it an increase in SP. This is because our new CEO CT starts on Friday and I believe news has been held back until he took up his position. We have 3 bits of news that are due.

1. Update on XF-73 partnering discussions. This could be provided in the results Rns or we could potentially get a separate Rns if the company have entered exclusive discussions with a Global pharma.

2. NIAID trial update, I am pretty confident that the trial results are very good. What I want to know is will NIAID now pay for clinical trials, if Yes expect a massive spike in share price.

3. Sporcov update, this will be interesting as Covid is on the rise again. Just a reminder that Sporcov kills all mutations of Covid unlike vaccines and does not need modifying.

The above is what we know but their could be other news also, as I believe someone has been accumulating.

September will be very busy news wise as the following are due.

1. Partnering discussions update for XF-73.

2. NIAID trial update

3. Sporcov update

As predicted it was Lunglife AI. See link below.

https://t.co/vgPdHVs48X

Krull, I had the same problem trying to buy it is nearly always NT. The way to get round it is to put in a tradeplan. That is what I did and my order got filled within a few minutes to my surprise.

However after I bought I tried a dummy sell and they were happy to take the lot of me in one go. Just shows how difficult it is to buy, so imagine how hard it will be to buy when the announce positive results for the trial. I think it will go ballistic.